Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 2/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.50 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.47 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.47 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.47 |
| ▸ | GRN | P28799 | 1/20 | 0.44 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 7/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.43 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.41 |
| ▸ | CCNC | P24863 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12705320 | 0.87 | GRN (0.59) | MAPK14MAPK13MAPK12MAPK11GRN | |
| SCHEMBL1140762 | 0.85 | PTGS2 (0.48) | MAPK14GRNSORT1CYP2C9PTGS2 | |
| SCHEMBL28293268 | 0.81 | SMN1; SMN2 (0.43) | CYP2C9 | |
| SCHEMBL9910542 | 0.78 | CDK8 (0.55) | CDK8MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL12364234 | 0.77 | CDK8 (0.63) | CDK8MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL12298702 | 0.76 | CDK8 (0.54) | CDK8MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL13263169 | 0.76 | GRN (0.57) | CDK8MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL23398880 | 0.75 | CDK8 (0.56) | CDK8MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL366727 | 0.75 | NPC1 (0.60) | CDK8MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL13234471 | 0.74 | CDK8 (0.52) | CDK8MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1670787-B1 | CYTOKINE INHIBITORS | ITHERX PHARMA INC (US) | 2012-05-30 | — | — | EP | disclosed |
| US-7919617-B2 | Cytokine inhibitors | iTherX Pharmaceuticals Inc. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7897599-B2 | Cytokine inhibitors | iTherX Pharmaceuticals Inc. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20100273797-A1 | ALPHA-KETOAMIDES AND DERIVATIVES THEREOF | ITHERX PHARMACEUTICALS, INC. | 2010-10-28 | — | — | US | disclosed |
| US-7749999-B2 | Alpha-ketoamides and derivatives thereof | ITHERX PHARMACEUTICALS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20100093734-A1 | CYTOKINE INHIBITORS | ITHERX PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093735-A1 | CYTOKINE INHIBITORS | ITHERX PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| EP-1670787-A4 | CYTOKINE INHIBITORS | KEMIA INC (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-1670787-A2 | CYTOKINE INHIBITORS | Kemia, INC. (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050107399-A1 | Cytokine inhibitors | KEMIA, INC. | 2005-05-19 | — | — | US | disclosed |
| WO-2005023761-A2 | CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107399-A1 | Cytokine inhibitors | TNF, IL1RN, IL1A | CDK8 2319/4885MAPK14 371/4885MAPK13 765/4885 |
| US-20100093734-A1 | CYTOKINE INHIBITORS | TNF, IL1RN, IL1A | CDK8 2319/4885MAPK14 371/4885MAPK13 765/4885 |
| US-20100273797-A1 | ALPHA-KETOAMIDES AND DERIVATIVES THEREOF | TNF, IL1A, IL1B | CDK8 988/4885MAPK14 696/4885MAPK13 1755/4885 |
| US-20100093735-A1 | CYTOKINE INHIBITORS | TNF, IL1RN, IL1A | CDK8 2319/4885MAPK14 371/4885MAPK13 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.